Recombinant factor VII associated with arterial thrombosis

Recombinant activated factor VII is FDA approved for use in hemophilia, but off-label use for bleeding (post-trauma and post-surgery) is common. This meta-analysis of all placebo controlled trials found the risk of arterial thrombosis was significantly higher with factor VII than with placebo (5.5% vs 3.2%); the risk of venous thrombosis was the same between the groups. Off-label use of factor VII significantly increases the risk of arterial thrombosis (abstract)

Danielle Scheurer

Dr. Scheurer is a clinical hospitalist and the Medical Director of Quality and Safety at the Medical University of South Carolina in Charleston, South Carolina, and is Assistant Professor of Medicine. She is a graduate of the University of Tennessee College of Medicine, completed her residency at Duke University, and completed her Masters in Clinical Research at the Medical University of South Carolina. She also serves as the Web Editor and Physician Advisor for the Society of Hospital Medicine.

Leave a Comment